Gentronix Goes East

Innovative biotechnology company Gentronix (Manchester, UK) is pleased to announce a new agreement with LSG Corporation (Tokyo, Japan). The deal enables introduction of the GreenScreen^® HC range of human cell-based genotoxicity assays across Japan, allowing scientists to accelerate the pace of drug discovery and development.

LSG has over 30 years’ experience providing researchers the tools and products required to solve even the toughest challenges within the life science arena. As a subsidiary of EPS Co., Ltd., one of the largest clinical research organisations in Japan, LSG is the ideal partner to promote the benefits of GreenScreen assays in this key market. GreenScreen HC, also available with a standardised S9 metabolic activation protocol, identifies genotoxic compounds in early screening of drug candidates. With a microplate format to enable high-throughput analysis, GreenScreen helps to remove the current bottlenecks commonly found in preclinical research and development.

Commercial director at Gentronix, Steve Beasley, comments: “We are delighted to have signed this agency agreement with LSG Corporation. LSG’s experience and extensive contacts in the Japanese life sciences and toxicology sectors will help to further develop our customer base in this important market.”